John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Anoperineal lesions Volume 25, issue 8, Octobre 2018

  • [1] Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn's disease in a population-based cohort. Dis Colon Rectum 2012 ; 55 : 773-7.
  • [2] Halme L., Sainio A.P. Factors related to frequency, type, and outcome of anal fistulas in Crohn's disease. Dis Colon Rectum. 1995;38:55-59.
  • [3] Kasparek M.S., Glatzle J., Temeltcheva T., Mueller M.H., Koenigsrainer A., Kreis M.E. Long-term quality of life in patients with Crohn's disease and perianal fistulas: Influence of fecal diversion. Dis Colon Rectum. 2007;50:2067-2074.
  • [4] Gu P, Kuenzig ME, Kaplan GG, Pimentel M, Rezaie A. Fecal incontinence in Inflammatory Bowel Disease : A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2018 ; 24 : 1280-90.
  • [5] Wisniewski A, Fléjou J-F, Siproudhis L, Abramowitz L, Svrcek M, Beaugerie L. Anal neoplasia in Inflammatory Bowel Disease : Classification proposal, epidemiology, carcinogenesis, and risk management perspectives. J Crohns Colitis 2017 ; 11 : 1011-8.
  • [6] Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.-P., Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
  • [7] Kirchgesner J., Lemaitre M., Rudnichi A., Racine A., Zureik M., Carbonnel F., Dray-Spira R. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents : analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther. 2017;45:37-49.
  • [8] Hughes L.E. Clinical classification of perianal Crohn's disease. Dis Colon Rectum. 1992;35:928-932.
  • [9] Schwartz DA, Ghazi LJ, Regueiro M, et al. ; Crohn's & Colitis Foundation of America, Inc. Guidelines for the multidisciplinary management of Crohn's perianal fistulas : summary statement. Inflamm Bowel Dis 2015 ; 21 : 723-30.
  • [10] Horaist C., de Parades V., Abramowitz L. Elaboration and validation of Crohn's disease anoperineal lesions consensual definitions. World J Gastroenterol. 2017;23:5371-5378.
  • [11] Garros A., Siproudhis L., Tchoundjeu B. Magnetic resonance imaging and clinical assessments for perianal Crohn's disease: Gain and limits. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2014;46:1072-1076.
  • [12] Van Assche G., Vanbeckevoort D., Bielen D. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
  • [13] Ford AC, Luthra P, Hanauer SB, Travis SP, Harris MS, Reinisch W. Placebo response rate in clinical trials of fistulizing Crohn's disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2014 ; 12 : 1981-90.
  • [14] Present D.H., Rutgeerts P., Targan S. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
  • [15] Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 ; 350 : 876-85.
  • [16] Panaccione R, Colombel J-F, Sandborn WJ, et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: Data from CHARM and ADHERE. Aliment Pharmacol Ther 2013 ; 38 : 1236-47.
  • [17] Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: Systematic review and meta-analysis. Arch Med Sci AMS 2013 ; 9 : 765-79.
  • [18] Yarur A.J., Kanagala V., Stein D.J. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017;45:933-940.
  • [19] Feagan B.G., Schwartz D., Danese S., Rubin D.T., Lissoos T.W., Xu J., Lasch K. Efficacy of vedolizumab in Fistulising Crohn's Disease: Exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12:621-626.
  • [20] Sands B.E., Gasink C., Jacobstein D. Fistula healing in pivotal studies of ustekinumab in Crohn's Disease. Gastroenterology. 2017;152:S185.
  • [21] Roumeguère P, Bouchard D, Pigot F, et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: Results from a prospective study. Inflamm Bowel Dis 2011 ; 17 : 69-76.
  • [22] Thomassin L., Armengol-Debeir L., Charpentier C. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease. World J Gastroenterol. 2017;23:4285-4292.
  • [23] Bouguen G., Siproudhis L., Gizard E. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975-981.
  • [24] Dewint P., Hansen B.E., Verhey E. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: A randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292-299.
  • [25] Legué C., Brochard C., Bessi G. Outcomes of perianal fistulising Crohn's Disease following anti-TNFα treatment discontinuation. Inflamm Bowel Dis. 2018;24:1107-1113.
  • [26] Haennig A, Staumont G, Lepage B, et al. The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease. Colorectal Dis 2015 ; 17 : 311-9.
  • [27] Wallenhorst T., Brochard C., Le Balch E. Anal ulcerations in Crohn's disease: Natural history in the era of biological therapy. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2017;49:1191-1195.
  • [28] Brochard C., Siproudhis L., Wallenhorst T. Anorectal stricture in 102 patients with Crohn's disease: Natural history in the era of biologics. Aliment Pharmacol Ther. 2014;40:796-803.
  • [29] Rozalén V., Parés D., Sanchez E. Advancement flap technique for anal fistula in patients with Crohn's Disease: A systematic review of the literature. Cirugia Espanola. 2017;95:558-565.
  • [30] Grimaud J-C, Munoz-Bongrand N, Siproudhis L, et al. ; Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology 2010 ; 138 : 2275-81.
  • [31] Senéjoux A, Siproudhis L, Abramowitz L, et al. ; Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif [GETAID]. Fistula plug in fistulising ano-perineal Crohn's Disease: A randomised controlled trial. J Crohns Colitis 2016 ; 10 : 141-8.
  • [32] Panés J, García-Olmo D, Van Assche G, et al. ; ADMIRE CD Stu dy Group Collaborators. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's Disease. Gastroenterology 2018 ; 154 : 1334-1342.